


Patient Assistance Programs (PAP)

Invokana®	Johnson & Johnson Patient Assistance Foundation
Farxiga®	AstraZeneca Prescription Savings Program
Jardiance®	Boehringer Ingelheim Cares PAP
Steglatro®	Merck Patient Assistance Program, Inc.
Trulicity®	Lilly Cares Foundation PAP
Victoza®	Novo Nordisk PAP
Rybelsus®	Novo Nordisk PAP
Kerendia®	Bayer US Patient Assistance Foundation



When to Refer to Nephrologist

- Indications to refer to nephrologist**
- Clinical findings inconsistent with typical diabetic nephropathy
 - Massive proteinuria
 - Hematuria, casts, and/or active urinary sediment
 - AKI or rapidly declining eGFR
 - Anemia of CKD
 - Complex comorbidities (e.g., hyperparathyroidism or bone disease)
 - Advanced CKD (i.e., eGFR <30 ml/min/1.73 m²)

Prognosis of CKD

		Persistent albuminuria categories (mg/g)			
		A1	A2	A3	
		Normal to Mildly Increased	Moderately Increased	Severely Increased	
		< 30	30-300	>300	
GFR categories (ml/min/1.73 m ²)	G1	Normal or high	≥ 90	Treat	Refer
	G2	Mildly decreased	60-89	Treat	Refer
	G3a	Mildly to moderately decreased	45-59	Treat	Refer
	G3b	Moderately to severely decreased	30-44	Treat	Refer
	G4	Severely decreased	15-29	Refer	Refer
G5	Kidney Failure	<15	Refer	Refer	



KDIGO 2012 clinical practice guideline for the evaluation https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf. Accessed February 6, 2022.

Conclusion

CKD carries a heavy burden economically and in quality of life

- 5% of Medicare patients have CKD associated with T2DM, yet expenditures account for 11%
- CKD associated with diabetes is the leading cause of ESRD
- Coordinated, multidisciplinary care with attention to appropriate, timely screening and preventative management is crucial to reducing morbidity and mortality

SGLT2i

- Data suggests a class effect on ↓ of CKD progression, in addition to CV benefits

GLP1-RA

- Data limited in severe CKD prevention compared to CVD benefits, use in significant CVD

Finerenone

- Monotherapy effects are unknown, use as alternative or add on therapy in high-risk CKD and CVD patients



Jain K, Molit AM. Comprehensive care for people with diabetic kidney disease. American Diabetes Association. <https://diabetesjournals.org/spectrum/article/28/3/187/32196/Comprehensive-Care-for-People-With-Diabetic-Kidney>. Published August 1, 2015. Accessed February 14, 2022.